InVivo Therapeutics (NSDQ:NVIV) today released 12-month results from the closed Inspire study of its neuro-spinal scaffold, touting improvements in ASIA impairment scales. The Cambridge, Mass.-based company’s neuro-spinal scaffold is a novel, biodegradable device designed to be surgically implanted following acute spinal cord injuries to act as a physical substrate for nerve sprouting. Of the 16 patients in […]
InVivo Therapeutics shares down as losses grow in Q2 earnings release
Shares in InVivo Therapeutics (NSDQ:NVIV) fell today after the medical device maker missed expectations on Wall Street with its second quarter results. The Cambridge, Mass-based company posted losses of $12.9 million, or $7.48 per share, up 104.1% as compared with the same period during the previous year. Losses per share were well behind the 41¢ expectations […]
InVivo closes $15m round
InVivo Therapeutics (NSDQ:NVIV) said today it closed a new public offering, bringing in approximately $15.2 million. In the round, the Cambridge, Mass.-based company floated 388,000 shares and another 388,000 warrants at a combined price of $2 per unit, plus 6.2 million pre-funded warrants and 6.2 million standard warrants at $1.99 apiece. The round also included an […]
InVivo Therapeutics prices $13m offering
InVivo Therapeutics (NSDQ:NVIV) today priced a public stock offering worth more than $13 million for the neurospinal scaffold it’s developing to treat spinal cord injuries. Cambridge, Mass.-based InVivo said it plans to float some 388,000 shares and another 388,000 warrants at a combined price of $2 per unit, plus 6.2 million pre-funded warrants and 6.2 million […]
InVivo prices $11m offering
InVivo Therapeutics (NSDQ:NVIV) has registered for a new offering of shares and warrants that could bring in approximately $11 million, according to an SEC filing. In the offering, the company will look to float approximately 1.5 million shares and 1.5 million Series A warrants at $7.40 per share. InVIvo Therapeutics has not yet announced the exercise […]
UPDATE: InVivo shares surge on release of 6-month results from cancelled Inspire trial
InVivo Therapeutics (NSDQ:NVIV) today has seen shares rise as much as 75% after it released complete six-month results from the company’s Inspire study of its neuro-spinal scaffold, which it ended in January after halting enrollment last July. Results were presented by Dr. Stuart Lee of Vidant Health at the 2018 AANS meeting yesterday, the Cambridge, Mass.-based […]
InVivo Therapeutics registers $8m offering
InVivo Therapeutics (NSDQ:NVIV) today registered for an upcoming offering, looking to raise approximately $8 million, according to an SEC filing. In the offering, the Cambridge, Mass.-based company will look to offer shares of common stock and Series A warrants. The offering is slated to include a 45-day underwriter’s option for the purchase of additional shares, according […]
InVivo plans 1-for-25 reverse stock split
InVivo Therapeutics (NSDQ:NVIV) said today it is initiating a 1-for-25 reverse split of its stock, looking to put a single share in the hands of its shareholders for every 25 shares they previously owned. The move will reduce the company’s authorized shares from 100 million to just four million, the Cambridge, Mass.-based company said, and is […]
InVivo wins FDA nod for new pivotal trial of its neuro-spinal scaffold
InVivo Therapeutics (NSDQ:NVIV) said today it won FDA investigational device exemption for a new pivotal trial of its neuro-spinal scaffold after ending the previous Inspire study of the device in January. The Cambridge, Mass.-based company’s neuro-spinal scaffold is a novel, biodegradable device designed to be surgically implanted following acute spinal cord injuries to act as a physical […]
Facing legal woes, PixarBio takes aim at InVivo
PixarBio (OTC:PXRB) faces its own legal problems: a possible lawsuit by the SEC, legal action by a disgruntled employee who is demanding unpaid wages and former landlords looking for $1.8 million in unpaid rent. But the 7-person biotech is also looking to launch some litigation of its own, according to a recent document it filed with the SEC […]
InVivo Therapeutics lifts Toselli to permanent prez, CEO | Personnel Moves February 6, 2018
InVivo Therapeutics (NSDQ:NVIV) said yesterday it made Dr. Richard Toselli’s spot in the corner office permanent, lifting him from acting CEO to prez and CEO. Dr. Toselli will maintain his position on the company’s board and as its chief medical officer, the position he was given when he joined the company last July. Prior to joining InVivo, […]
- 1
- 2
- 3
- …
- 16
- Next Page »
MassDevice Network
@MassDevice
LinkedIn
Google+